Georges Gemayel

Georges Gemayel (senior executive) discloses dealings in 3 companies, chiefly Supernus Pharmaceuticals, Inc., Momenta Pharmaceuticals Inc and Raptor Pharmaceutical Corp. We count 21 filings; the first trade dates from 15 April 2016 and the latest from 5 March 2026.

Sales make up the whole of the open-market record (4 sales, €1.1M). Other entries cover 7 share grants and 7 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

On 9 March 2026 came the latest disclosure, an open-market sale for €462k in Supernus Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.